CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:
We lower our 12-month price target from $140 to $120, reflecting an 18.3x P/E multiple of our unchanged FY 27 (Oct.) EPS estimate of $6.57 (FY 26 EPS estimate raised $0.01 to $5.97), a discount to Agilent's one- and three-year historical forward averages of 20.2x and 21.2x, respectively. We think headwinds may persist across key life sciences end markets due to macroeconomic pressures, uncertain tariff and research funding policy, and weaker biotech spending and clinical trial activity. Our target multiple is near recent forward valuations for key life sciences tools & services peers Danaher Corporation (DHR), Thermo Fisher Scientific Inc. (TMO), Waters Corporation (WAT), and Revvity Inc. (RVTY). The sub-industry recently traded at a roughly 25% discount to its three-year historical forward average. Agilent will report Q2 FY 26 earnings after the market close on May 27, when we anticipate 7.5%-8.0% comparable growth in both sales and EPS.